Emphysema Treatment Market By Medication Type (Bronchodilators, Steroids, Others), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

Emphysema Treatment Market By Medication Type (Bronchodilators, Steroids, Others), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

The Emphysema Treatment Market valued for $4,474.71 million in 2021 and is estimated to reach $7,292.90 million by 2031, exhibiting a CAGR of 5% from 2022 to 2031.

Emphysema and chronic bronchitis are the most common conditions that make up chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease is a group of lung diseases that block airflow and make it difficult to breathe. Abnormalities in the small airways of the lungs lead to limitation of airflow in and out of the lungs. Several processes cause the airways to become narrow. There may be destruction of parts of the lung, mucus blocking the airways, and inflammation & swelling of the airway lining. COPD is sometimes called emphysema or chronic bronchitis. Emphysema usually refers to destruction of the tiny air sacs at the end of the airways in the lungs. There is no cure for COPD, however early diagnosis and treatment are important to slow the progression of symptoms and reduce the risk of flare-ups.

The driving factors for emphysema treatment market are increase in prevalence of emphysema across the world owing to rise in number of smokers in many regions. For instance, according to article published in National Library of Medicine, 2022, prevalence of emphysema in U.S., is approximately 14 million and is leading COPD disorder across the country. In addition, to eliminate the occurrence and progression of condition associated with chronic obstructive pulmonary disease (COPD), early diagnosis and treatment is essential, which contributes to growth of emphysema treatment market. For instance, according to an article published in National Library of Medicine 2022, prevalence of chronic obstructive pulmonary disease (COPD) is increasing in North India accounting for 19.4% and Bangladesh with 13.5%. Further, surge in number of smokers across the globe results in increase in prevalence of emphysema, thereby driving the market growth. For instance, according to World Health Organization (WHO) 2021, 22.3% world’s population used tobacco with 1.3 million tobacco smokers residing in low and middle-income countries. Thus, increase in prevalence of emphysema cases, rise in number of smokers, awareness regarding emphysema, and treatment drive the growth of emphysema treatment market during forecast period.

However, side effects of the drug used in emphysema treatment restrain the growth of emphysema treatment market. In addition, failure of new drugs in clinical trials, also might hinder the growth of market.

The global emphysema treatment market is segmented into medication type, distribution channel, and region. On the basis of medication type, the market is segregated into bronchodilators, steroids, and others. On the basis of distribution channel, the market is categorized into hospitals pharmacies, online providers, and drug stores and retail pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global Emphysema treatment market are AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Mylan Pharmaceuticals (Viatris), Teva Pharmaceuticals, Hikma Pharmaceuticals Plc, Orion Corporation, Pfizer, Inc., and Verona pharma.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the emphysema treatment market analysis from 2021 to 2031 to identify the prevailing emphysema treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the emphysema treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global emphysema treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Medication Type

Bronchodilators
Steroids
Others

By Distribution Channel

Online Providers
Drug Stores and Retail Pharmacies
Hospital Pharmacies

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Pfizer, Inc.
teva pharmaceuticals
orion corporation
GlaxoSmithKline plc
Hikma Pharmaceuticals plc
Verona Pharma
Novartis AG
AstraZeneca
Boehringer Ingelheim International GmbH
Mylan Pharmaceuticals ( a subsidiary of Viatris)

Please Note: It will take 7-10 business days to complete the report upon order confirmation.